[THE INVESTOR] On Oct. 17, Mezzion Pharma (140410) declined 3.92% to 22,050 won (US$19.38). It had declined 11.98% through the past month. Standard deviation, which indicates variableness, records 2.7% over the same period of time over one month.
Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Mezzion Pharma was not so high, the earnings rate for one month was also the lowest with decline of stock price. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -4.4%. As high volatility and a bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, 1.7, and thus the industrial comparison performance was not so good.
From Oct. 10, institutions have been continuously buying Mezzion Pharma during the past five trading days. As a shareholding sum by investor group for the past four weeks, foreigners have bought 3,504 shares with a maintenance of shareholding and individuals have bought 6,279 shares lessening its position. However, during the same period, institutions have sold 9,783 shares with dominant selling.
| Cumulated shareholdings per investor group (1Mo) | Total shareholdings per investor group | |
 |
 |
By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.
